Article

Adam Friedman, MD: Returning to Normal During the COVID-19 Pandemic

Author(s):

Since the beginning of the COVID-19 pandemic most non-urgent medical appointments have been conducted using telehealth.

The coronavirus disease 2019 (COVID-19) pandemic has uprooted virtually every business across the globe, including the healthcare industry.

Appointments and checkups have been cancelled or moved to virtual settings and research and elective surgeries have been put on hold until researchers have a better grasp on how to treat the growing number of patients coming down with the virus.

In fields like dermatology, the transition to telemedicine was smooth, but there is still a need to return to an office setting. However, by all accounts, those visits to a doctor’s office or a hospital cannot occur until the risk for both the patient and medical staff is substantially reduced.

In an interview with HCPLIVE®, Adam Friedman, MD, Professor & Interim Chair of Dermatology at The George Washington University School of Medicine and Health Sciences, said there is some hope that live appointments may be able to resume soon, at least in the Washington D.C. area.

Friedman also explained how dermatologists were able to transition to telehealth once it was decided it wasn’t safe for live appointments to occur during the early stages of the pandemic.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.